Department of Tropical Medicine and Infectious Diseases, Tanta University Hospitals, Tanta Faculty of Medicine, Tanta - Egypt.
Int J Biol Markers. 2012 Jul 19;27(2):e125-31. doi: 10.5301/JBM.2012.9097.
To evaluate the role of chemokine CC ligand 20 (CCL20) as a biomarker for hepatocellular carcinoma (HCC).
Ninety patients in four groups were enrolled in this prospective cross-sectional study: 30 with HCC (group I), 30 with liver cirrhosis (group II), 15 with hepatitis C virus infection (group III), and 15 healthy blood donors as controls. Alpha fetoprotein (AFP), CCL20 and vascular endothelial growth factor (VEGF) were measured in all groups.
Serum levels of CCL20 were significantly different among the study groups (F=230.979, p<0.001). The highest level was found in HCC patients (57.305 ± 6.386 pg/mL) followed by patients with cirrhosis (45.999 ± 5.165 pg/mL) compared with 22.781 ± 5.986 pg/mL and 18.585 ± 3.554 pg/mL in asymptomatic patients with HCV infection and controls, respectively. In HCC patients, CCL20 significantly correlated with VEGF (r=0.559, p=0.001), AFP (r=0.814, p<0.001), Child score (r=0.748, p<0.001), and tumor size (r=0.825, p<0.001). The cutoff value of CCL20 for the detection of HCC in HCV-infected patients was 54 pg/mL with 93.1% accuracy, 89.6% negative predictive value, 92.6% positive predictive value, 83.3% sensitivity, and 93.3% specificity. In patients with cirrhosis, CCL20 significantly correlated with VEGF (r=0.455, p=0.011), AFP (r=0.975, p<0.001), and Child score (r=0.977, p<0.001).
CCL20 may be used for the detection of HCC in HCV-infected patients with comparable specificity and higher sensitivity than AFP.
评估趋化因子 CC 配体 20（CCL20）作为肝细胞癌（HCC）生物标志物的作用。
本前瞻性横断面研究纳入了四组 90 名患者：30 名 HCC 患者（I 组）、30 名肝硬化患者（II 组）、15 名丙型肝炎病毒感染患者（III 组）和 15 名健康献血者作为对照组。所有组均测量了甲胎蛋白（AFP）、CCL20 和血管内皮生长因子（VEGF）。
研究组之间血清 CCL20 水平存在显著差异（F=230.979，p<0.001）。HCC 患者的水平最高（57.305±6.386pg/mL），其次是肝硬化患者（45.999±5.165pg/mL），而无症状丙型肝炎病毒感染患者和对照组分别为 22.781±5.986pg/mL 和 18.585±3.554pg/mL。在 HCC 患者中，CCL20 与 VEGF（r=0.559，p=0.001）、AFP（r=0.814，p<0.001）、Child 评分（r=0.748，p<0.001）和肿瘤大小（r=0.825，p<0.001）显著相关。CCL20 检测丙型肝炎病毒感染患者 HCC 的截断值为 54pg/mL，其准确性为 93.1%，阴性预测值为 89.6%，阳性预测值为 92.6%，灵敏度为 83.3%，特异性为 93.3%。在肝硬化患者中，CCL20 与 VEGF（r=0.455，p=0.011）、AFP（r=0.975，p<0.001）和 Child 评分（r=0.977，p<0.001）显著相关。
CCL20 可用于检测丙型肝炎病毒感染患者的 HCC，其特异性与 AFP 相当，而灵敏度更高。
